DARATUMUMAB
UC (Urothelial Cancer)
Incyte Corporationmonoclonal_antibodyPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the UC (Urothelial Cancer) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Epacadostat Incyte Corporation | Phase 3 | BB |
mk-3475 Incyte Corporation | Phase 1/2 | CCC |
Decoy20 Indaptus Therapeutics, Inc | Phase 1/2 | CCC |
NUMIDARGISTAT Incyte Corporation | Phase 1 | CC |
Parsaclisib Incyte Corporation | Phase 1 | CC |
Itacitinib Incyte Corporation | Phase 1 | CC |
Incb053914 Incyte Corporation | Phase 1 | C |
Same molecule, other indications
DARATUMUMAB is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →